Cytokinetics Inc (CYTK) stock
CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$56.13−0.03 (-0.05%)
Close on Nov 13, 2026Market cap $7.80BP/E –Yield –
Cytokinetics operating margin
Operating margin is operating income as a percentage of revenue.
Cytokinetics's operating margin for the twelve months ending Sep 30, 2026 was -625.2%. For fiscal 2025 it was -695.4%, against -2902.7% the year before. The highest annual figure on record is 32.0% in fiscal 2009.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -695.4% | +2207.3 |
| FY2024 | Dec 31, 2024 | -2902.7% | +3687.0 |
| FY2023 | Dec 31, 2023 | -6589.7% | −6247.0 |
| FY2022 | Dec 31, 2022 | -342.8% | −78.2 |
| FY2021 | Dec 31, 2021 | -264.5% | −96.3 |
| FY2020 | Dec 31, 2020 | -168.3% | +199.7 |
| FY2019 | Dec 31, 2019 | -368.0% | −85.7 |
| FY2018 | Dec 31, 2018 | -282.3% | +566.0 |
| FY2017 | Dec 31, 2017 | -848.3% | −865.8 |
| FY2016 | Dec 31, 2016 | 17.6% | +148.1 |
| FY2015 | Dec 31, 2015 | -130.5% | −99.1 |
| FY2014 | Dec 31, 2014 | -31.4% | +79.2 |
| FY2013 | Dec 31, 2013 | -110.6% | +424.6 |
| FY2012 | Dec 31, 2012 | -535.2% | +663.9 |
| FY2011 | Dec 31, 2011 | -1199.1% | +727.0 |
| FY2010 | Dec 31, 2010 | -1926.1% | −1958.1 |
| FY2009 | Dec 31, 2009 | 32.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -351.3% | +8262.0 |
| Q2 FY2026 | Jun 30, 2026 | -626.0% | −458.9 |
| Q1 FY2026 | Mar 31, 2026 | -948.7% | +8907.6 |
| Q4 FY2025 | Dec 31, 2025 | -1004.6% | −183.2 |
| Q3 FY2025 | Sep 30, 2025 | -8613.4% | +21797.2 |
| Q2 FY2025 | Jun 30, 2025 | -167.0% | +52110.9 |
| Q1 FY2025 | Mar 31, 2025 | -9856.3% | +5261.7 |
| Q4 FY2024 | Dec 31, 2024 | -821.4% | +6799.3 |
| Q3 FY2024 | Sep 30, 2024 | -30410.6% | +1934.7 |
| Q2 FY2024 | Jun 30, 2024 | -52277.9% | −38200.7 |
| Q1 FY2024 | Mar 31, 2024 | -15118.0% | −12419.7 |
| Q4 FY2023 | Dec 31, 2023 | -7620.7% | −1129.6 |
| Q3 FY2023 | Sep 30, 2023 | -32345.2% | −28033.5 |
| Q2 FY2023 | Jun 30, 2023 | -14077.2% | −14064.9 |
| Q1 FY2023 | Mar 31, 2023 | -2698.3% | +4083.7 |
| Q4 FY2022 | Dec 31, 2022 | -6491.1% | −6452.0 |
| Q3 FY2022 | Sep 30, 2022 | -4311.8% | −3039.0 |
| Q2 FY2022 | Jun 30, 2022 | -12.2% | +1915.2 |
| Q1 FY2022 | Mar 31, 2022 | -6782.0% | −6161.8 |
| Q4 FY2021 | Dec 31, 2021 | -39.0% | +502.6 |
| Q3 FY2021 | Sep 30, 2021 | -1272.8% | −1285.2 |
| Q2 FY2021 | Jun 30, 2021 | -1927.4% | −1026.9 |
| Q1 FY2021 | Mar 31, 2021 | -620.2% | +173.6 |
| Q4 FY2020 | Dec 31, 2020 | -541.6% | −86.8 |
| Q3 FY2020 | Sep 30, 2020 | 12.4% | +407.6 |
| Q2 FY2020 | Jun 30, 2020 | -900.6% | −526.3 |
| Q1 FY2020 | Mar 31, 2020 | -793.8% | −504.1 |
| Q4 FY2019 | Dec 31, 2019 | -454.8% | −226.0 |
| Q3 FY2019 | Sep 30, 2019 | -395.2% | −226.8 |
| Q2 FY2019 | Jun 30, 2019 | -374.3% | +2.4 |
| Q1 FY2019 | Mar 31, 2019 | -289.7% | +206.4 |
| Q4 FY2018 | Dec 31, 2018 | -228.8% | +231.1 |
| Q3 FY2018 | Sep 30, 2018 | -168.3% | +656.9 |
| Q2 FY2018 | Jun 30, 2018 | -376.7% | +183.1 |
| Q1 FY2018 | Mar 31, 2018 | -496.0% | −519.2 |
| Q3 FY2017 | Sep 30, 2017 | -459.9% | – |
| Q2 FY2017 | Jun 30, 2017 | -825.2% | – |
| Q1 FY2017 | Mar 31, 2017 | -559.9% | – |
| Q4 FY2016 | Dec 31, 2016 | 23.2% | – |
See a number that looks wrong?